Skip to main content
EHTH logo

EHTH · eHealth, Inc.

Track EHTH — free
$0.92 0.00 (-0.26%)
Market Cap
$29.57M
Shares
32.03M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.92 Open$0.92 Day$0.92–0.94 52W close$0.92–5.65 Avg vol 30d296K Short int571K · 1.8% float · 2.6d Short vol60% Last earningsAug 4, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 7 wks
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$501.69M
Trailing 12 months
Net income (TTM)
$27.18M
Trailing 12 months
Revenue growth YoY
-44.8%
Year over year
Operating margin
10.8%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
-105.3%
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+4.5%
Year over year · more shares
Price change (1Y)
-77.0%
Trailing year
Short interest
1.8%
Latest settlement · 2.6 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. eHealth (EHTH) reported Q2 2026 revenue of $33.6M, down 45% YoY, as it deliberately reduced marketing spend outside major enrollment periods to focus advisors on its newly launched lifetime advisory model. The company reiterated full-year 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow, while updating net adjustment (tail) revenue guidance to $16M–$20M (from $8M–$20M) to reflect the $7.6M of Q2 tail revenue.

Bullish
  • + Reiterated full-year 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow and raised net adjustment revenue outlook to $16M–$20M from $8M–$20M.
  • + Operating cash flow improved $36.2M year-over-year in Q2 to $(5.0)M vs. $(41.2)M, supporting meaningful YoY operating cash flow improvement for the year.
  • + Q2 ancillary product cross-sell rates doubled YoY and other member engagement metrics improved, providing early validation of the new lifetime advisory model launched in Q2.
  • + Non-GAAP operating expenses declined 25% YoY in Q2, on track for >$60M variable and ~$30M fixed annual cost savings vs. prior year.
  • + Positive net adjustment (tail) revenue of $7.6M in Q2, bringing cumulative tail revenue to $284M since 2018, and commissions receivable grew 10% YoY to $1.0B.
Bearish
  • Q2 total revenue fell 45% YoY to $33.6M and Medicare segment revenue fell 45% YoY to $31.8M, driven by lower Medicare enrollment volume and lower tail revenue.
  • GAAP net loss widened to $(23.6)M from $(17.4)M and adjusted EBITDA loss deepened to $(21.8)M from $(14.1)M year-over-year.
  • Management expects an even greater YoY decline in Q3 enrollment volume and revenue than the 45% Q2 marketing cut, as the majority of marketing spend is deferred to Q4 AEP.
  • Medicare segment gross profit fell 69% YoY to $6.0M from $19.1M, with $10.0M of the decline attributable to lower tail revenue.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.67
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −56%
below
Price vs 50-day avg −28%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −24%
trailing
6-month return −38%
trailing
YTD return −80%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.78% of float · ▲ +0.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
105 holders — mid 3-yr range
Squeeze score 39
low risk · 0–100
Fundamentals
Excellent
Revenue growth +32%
Y/Y
Gross margin 96%
contracting
EPS growth +71%
Y/Y
Free cash flow $-27.6M
Buyback $50.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 94%
annualized · 1-yr
Max drawdown −84%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 3
Latest guidance · from the 8-K filed Aug 4, 2026
Total revenue · full year ending December 31, 2026 Initiated $405M – $445M
prior FY $554.01M midpoint −23.3% Y/Y
GAAP net income · full year ending December 31, 2026 Initiated $8M – $25M
Positive net adjustment revenue · full year ending December 31, 2026 Initiated $16M – $20M
Adjusted EBITDA · full year ending December 31, 2026 Initiated $55M – $75M
Prior guidance period ended · from the 8-K filed Aug 7, 2024
Total revenue · full year ending December 31, 2024 $470M – $495M
GAAP net income (loss) · full year ending December 31, 2024 $-36.5M – $-22M
Guided vs delivered · last 3 settled
Total revenue full year ending December 31, 2024
guided $470M – $495M
$532.41M Beat +10.3%
Total revenue 2021 annual
guided $535M – $575M
$538.2M In line
GAAP net income per diluted share 2021
guided $1.53 – $2.08
$-4.59 Miss −354.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−56% Bearish
Price vs 50-day avg
−28% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.78% of float · ▲ +0.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $6
vs 200-day avg -56% vs 50-day avg -28%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Insurance Brokers — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EHTH
eHealth, Inc.
this stock
$29.57M -79.9% +31.8% 1.8%
MRSH
Marsh & Mclennan Companies, Inc.
$84.42B -2.7% +10.3% 21.6 1.4%
AON
Aon plc
$64.97B -11.7% +7.7% 16.9 1.8%
AJG
Arthur J. Gallagher & Co.
$64.02B -2.1% +10.1% 41.4 2.6%
WTW
Willis Towers Watson PLC
$29.31B -1.5% -2.2% 19.6 2.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
105
% held
50.1%
Net QoQ
-972.0K sh
Top holder
AQR CAPITAL MANAGEMENT LLC
Held Float
View
Held by Funds
Fund positions
74
View
Short & Settlement
Short Interest Rising
Shares short
570.9K
Days to cover
2.6d
Change
+1.7K sh
View
Short Volume
Short vol %
60%
As of
Sep 14, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$2.1K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
44.8%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$554.0M
Net income (FY)
$40.0M
EPS diluted
$-0.34
View
Buybacks
Authorized
$50.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 5, 2026
This year
10
View
Proposed Sales
Value
$39.3K
Shares
37.3K
Filed
Sep 1, 2026
View
Exempt Offerings
Offering
$225.0M
Filed
May 14, 2021
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View
Investor Relations
Latest news
New Survey: Americans are Confide…
Published
Aug 20, 2026
View

Performance

5D 20D 120D MTD YTD
EHTH -6.8% -24.3% -38.5% -18.3% -79.9%
SPY -1.2% -2.0% +16.1% -0.8% +11.6%
vs SPY -5.6% -22.4% -54.6% -17.5% -91.5%

Capital returns

Buyback program · as of Mar 31, 2014
Authorized
$50.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1333493 CUSIP 28238P109 13F (30d) 7 filings 7 filers Visit website Investor relations